Neuropathic Pain in Aged People: An Unresolved Issue Open to Novel Drug Approaches, Focusing on Painful Diabetic Neuropathy


Cite item

Full Text

Abstract

A majority of older patients suffer from neuropathic pain (NP) that significantly alters their daily activities and imposes a significant burden on health care. Multiple comorbidities and the risk of polypharmacy in the elderly make it challenging to determine the appropriate drug, dosage, and maintenance of therapy. Age-dependent processes play a contributing role in neuropathy given that diabetic neuropathy (DN) is the most common form of neuropathy. This narrative review is mainly focused on the drug treatment approach for neuropathy-associated pain in aged people including both drugs and dietary supplements, considering the latter as add-on mechanism-based treatments to increase the effectiveness of usual treatments by implementing their activity or activating other analgesic pathways. On one hand, the limited clinical studies assessing the effectiveness and the adverse effects of existing pain management options in this age segment of the population (> 65), on the other hand, the expanding global demographics of the elderly contribute to building up an unresolved pain management problem that needs the attention of healthcare providers, researchers, and health authorities as well as the expansion of the current therapeutic options.

About the authors

Nicoletta Marchesi

Department of Drug Sciences, Section of Pharmacology, University of Pavia

Author for correspondence.
Email: info@benthamscience.net

Foroogh Fahmideh

Department of Drug Sciences, Section of Pharmacology, University of Pavia

Email: info@benthamscience.net

Alessia Pascale

Department of Drug Sciences, Section of Pharmacology, University of Pavia

Email: info@benthamscience.net

Massimo Allegri

, Ensemble Hospitalier de la Cote - Centre Lemanique d’antalgie et Neuromodulation

Email: info@benthamscience.net

Stefano Govoni

Department of Drug Sciences, Section of Pharmacology, University of Pavia

Email: info@benthamscience.net

References

  1. Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Kamerman, P.R.; Lund, K.; Moore, A.; Raja, S.N.; Rice, A.S.C.; Rowbotham, M.; Sena, E.; Siddall, P.; Smith, B.H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol., 2015, 14(2), 162-173. doi: 10.1016/S1474-4422(14)70251-0 PMID: 25575710
  2. Allegri, N.; Mennuni, S.; Rulli, E.; Vanacore, N.; Corli, O.; Floriani, I. Systematic review and meta-analysis on neuropsychological effects of long-term use of opioids in patients with chronic noncancer pain. Pain Pract., 2018, 19(3), 328-343. doi: 10.1111/papr.12741
  3. Tsai, Y.I.; Browne, G.; Inder, K.J. Nurses’ perspectives of pain assessment and management in dementia care in hospital. Australas. J. Ageing, 2023, 42(2), 382-391. doi: 10.1111/ajag.13146
  4. Tsai, Y.I.P.; Browne, G.; Inder, K.J. The effectiveness of interventions to improve pain assessment and management in people living with dementia: A systematic review and meta‐analyses. J. Adv. Nurs., 2021, 77(3), 1127-1140. doi: 10.1111/jan.14660 PMID: 33222273
  5. Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A.H.; Yarnitsky, D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N.B.; Eccleston, C.; Kalso, E.; Bennett, D.L.; Dworkin, R.H.; Raja, S.N. Neuropathic pain. Nat. Rev. Dis. Primers, 2017, 3(1), 17002. doi: 10.1038/nrdp.2017.2 PMID: 28205574
  6. Kandil, A.; Perret, D. Classification of Neuropathic Pain. In: Neuropathic Pain; Oxford University Press: Oxford, UK, 2018; pp. 11-16. doi: 10.1093/med/9780190298357.003.0002
  7. Giovannini, S.; Coraci, D.; Brau, F.; Galluzzo, V.; Loreti, C.; Caliandro, P.; Padua, L.; Maccauro, G.; Biscotti, L.; Bernabei, R. Neuropathic pain in the elderly. Diagnostics, 2021, 11(4), 613. doi: 10.3390/diagnostics11040613 PMID: 33808121
  8. Salman, R.R.; Delbari, A.; Asadi-Lari, M.; Rashedi, V.; Lökk, J. Neuropathic pain prevalence of older adults in an urban area of Iran: A population-based study. Pain Res. Treat., 2019, 2019, 1-8. doi: 10.1155/2019/9015695 PMID: 30719350
  9. Stompór, M.; Grodzicki, T.; Stompór, T.; Wordliczek, J.; Dubiel, M.; Kurowska, I. Prevalence of chronic pain, particularly with neuropathic component, and its effect on overall functioning of elderly patients. Med. Sci. Monit., 2019, 25, 2695-2701. doi: 10.12659/MSM.911260 PMID: 31018630
  10. van Hecke, O.; Austin, S.K.; Khan, R.A.; Smith, B.H.; Torrance, N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain, 2014, 155(4), 654-662. doi: 10.1016/j.pain.2013.11.013 PMID: 24291734
  11. Loeser, J.D.; Treede, R.D. The kyoto protocol of IASP basic pain terminology. Pain, 2008, 137(3), 473-477. doi: 10.1016/j.pain.2008.04.025 PMID: 18583048
  12. Wood, M. Understanding pain in herpes zoster: An essential for optimizing treatment. J. Infect. Dis., 2002, 186(S1), S78-S82. doi: 10.1086/342958 PMID: 12353191
  13. Kieseier, B.C.; Mathey, E.K.; Sommer, C.; Hartung, H.P. Immune-mediated neuropathies. Nat. Rev. Dis. Primers, 2018, 4(1), 31. doi: 10.1038/s41572-018-0027-2 PMID: 30310069
  14. Belmin, J.; Valensi, P. Diabetic neuropathy in elderly patients. What can be done? Drugs Aging, 1996, 8(6), 416-429. doi: 10.2165/00002512-199608060-00003 PMID: 8736625
  15. Vinik, A.I.; Strotmeyer, E.S.; Nakave, A.A.; Patel, C.V. Diabetic neuropathy in older adults. Clin. Geriatr. Med., 2008, 24(3), 407-435. v. doi: 10.1016/j.cger.2008.03.011 PMID: 18672180
  16. Pop-Busui, R.; Boulton, A.J.M.; Feldman, E.L.; Bril, V.; Freeman, R.; Malik, R.A.; Sosenko, J.M.; Ziegler, D. Diabetic neuropathy: A position statement by the american diabetes association. Diabetes Care, 2017, 40(1), 136-154. doi: 10.2337/dc16-2042 PMID: 27999003
  17. Pfannkuche, A.; Alhajjar, A.; Ming, A.; Walter, I.; Piehler, C.; Mertens, P.R. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative diabetes and nerves. End. Metabol. Sci., 2020, 1(1-2), 100053. doi: 10.1016/j.endmts.2020.100053
  18. Davies, M.; Brophy, S.; Williams, R.; Taylor, A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care, 2006, 29(7), 1518-1522. doi: 10.2337/dc05-2228 PMID: 16801572
  19. Dyck, P.J.; Kratz, K.M.; Karnes, J.L.; Litchy, W.J.; Klein, R.; Pach, J.M.; Wilson, D.M.; O’Brien, P.C.; Melton, L.J., III; Service, F.J. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology, 1993, 43(4), 817-824. doi: 10.1212/WNL.43.4.817 PMID: 8469345
  20. Simo, N.; Kuate-Tegueu, C.; Ngankou-Tchankeu, S.; Doumbe, J.; Maiga, Y.; Cesari, M.; Dartigues, J.F.; Kengne, A.P.; Tabue-Teguo, M. Correlates of diabetic polyneuropathy of the elderly in Sub-Saharan Africa. PLoS One, 2020, 15(10), e0240602. doi: 10.1371/journal.pone.0240602 PMID: 33119646
  21. Baderca, F.; Timar, B.; Popescu, S.; Simu, M.; Diaconu, L.; Velea, I.; Timar, R. Age as an independent factor for the development of neuropathy in diabetic patients. Clin. Interv. Aging, 2016, 11, 313. doi: 10.2147/CIA.S97295
  22. Poliakov, I.; Toth, C. The impact of pain in patients with polyneuropathy. Eur. J. Pain, 2011, 15(10), 1015-1022. doi: 10.1016/j.ejpain.2011.04.013 PMID: 21600817
  23. Tracy, B.; Sean Morrison, R. Pain management in older adults. Clin. Ther., 2013, 35(11), 1659-1668. doi: 10.1016/j.clinthera.2013.09.026 PMID: 24148553
  24. Defrin, R.; Amanzio, M.; de Tommaso, M.; Dimova, V.; Filipovic, S.; Finn, D.P.; Gimenez-Llort, L.; Invitto, S.; Jensen-Dahm, C.; Lautenbacher, S.; Oosterman, J.M.; Petrini, L.; Pick, C.G.; Pickering, G.; Vase, L.; Kunz, M. Experimental pain processing in individuals with cognitive impairment. Pain, 2015, 156(8), 1396-1408. doi: 10.1097/j.pain.0000000000000195 PMID: 26181216
  25. Hicks, C.W.; Selvin, E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr. Diab. Rep., 2019, 19(10), 86. doi: 10.1007/s11892-019-1212-8 PMID: 31456118
  26. Giovannini, S.; Onder, G.; Leeuwenburgh, C.; Carter, C.; Marzetti, E.; Russo, A.; Capoluongo, E.; Pahor, M.; Bernabei, R.; Landi, F. Myeloperoxidase levels and mortality in frail community-living elderly individuals. J. Gerontol. A Biol. Sci. Med. Sci., 2010, 65A(4), 369-376. doi: 10.1093/gerona/glp183 PMID: 20064836
  27. Edwards, J.L.; Vincent, A.M.; Cheng, H.T.; Feldman, E.L. Diabetic neuropathy: Mechanisms to management. Pharmacol. Ther., 2008, 120(1), 1-34. doi: 10.1016/j.pharmthera.2008.05.005 PMID: 18616962
  28. Pop-Busui, R.; Sima, A.; Stevens, M. Diabetic neuropathy and oxidative stress. Diabetes Metab. Res. Rev., 2006, 22(4), 257-273. doi: 10.1002/dmrr.625 PMID: 16506271
  29. Bruunsgaard, H.; Pedersen, M.; Pedersen, B.K. Aging and proinflammatory cytokines. Curr. Opin. Hematol., 2001, 8(3), 131-136. doi: 10.1097/00062752-200105000-00001 PMID: 11303144
  30. Takeshita, Y.; Sato, R.; Kanda, T. Blood-Nerve Barrier (BNB) pathology in diabetic peripheral neuropathy and in vitro human BNB model. Int. J. Mol. Sci., 2020, 22(1), 62. doi: 10.3390/ijms22010062 PMID: 33374622
  31. Xu, X.; Wang, B.; Ren, C.; Hu, J.; Greenberg, D.A.; Chen, T.; Xie, L.; Jin, K. Age-related impairment of vascular structure and functions. Aging Dis., 2017, 8(5), 590-610. doi: 10.14336/AD.2017.0430 PMID: 28966804
  32. Jaruchart, T.; Suwanwela, N.C.; Tanaka, H.; Suksom, D. Arterial stiffness is associated with age-related differences in cerebrovascular conductance. Exp. Gerontol., 2016, 73, 59-64. doi: 10.1016/j.exger.2015.11.006 PMID: 26571202
  33. Perucca, E.; Berlowitz, D.; Birnbaum, A.; Cloyd, J.C.; Garrard, J.; Hanlon, J.T.; Levy, R.H.; Pugh, M.J. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res., 2006, 68(Suppl. 1), 49-63. doi: 10.1016/j.eplepsyres.2005.07.017 PMID: 16207524
  34. Cusack, B.J. Pharmacokinetics in older persons. Am. J. Geriatr. Pharmacother., 2004, 2(4), 274-302. doi: 10.1016/j.amjopharm.2004.12.005 PMID: 15903286
  35. Burris, J.E. Pharmacologic approaches to geriatric pain management11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors(s) or upon any organization with which the author(s) is/are associated. Arch. Phys. Med. Rehabil., 2004, 85(7)(Suppl. 3), 45-49. doi: 10.1016/j.apmr.2004.03.011 PMID: 15221725
  36. Pharmacodynamics in Older Adults - Geriatrics. MSD Manual Professional Edition. Available from: https://www.msdmanuals.com/professional/geriatrics/drug-therapy-in-older-adults/pharmacodynamics-in-older-adults
  37. Bates, D.; Schultheis, B.C.; Hanes, M.C.; Jolly, S.M.; Chakravarthy, K.V.; Deer, T.R.; Levy, R.M.; Hunter, C.W. A Comprehensive algorithm for management of neuropathic pain. Pain Med., 2019, 20(Suppl. 1), S2-S12. doi: 10.1093/pm/pnz075 PMID: 31152178
  38. Semel, D.; Murphy, T.K.; Zlateva, G.; Cheung, R.; Emir, B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam. Pract., 2010, 11(1), 85. doi: 10.1186/1471-2296-11-85 PMID: 21054853
  39. Dallocchio, C.; Buffa, C.; Mazzarello, P.; Chiroli, S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J. Pain Symptom Manage., 2000, 20(4), 280-285. doi: 10.1016/S0885-3924(00)00181-0 PMID: 11027910
  40. Boyle, J.; Eriksson, M.E.V.; Gribble, L.; Gouni, R.; Johnsen, S.; Coppini, D.V.; Kerr, D. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care, 2012, 35(12), 2451-2458. doi: 10.2337/dc12-0656 PMID: 22991449
  41. Watson, P.C.N.; Moulin, D.; Watt-Watson, J.; Gordon, A.; Eisenhoffer, J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain, 2003, 105(1), 71-78. doi: 10.1016/S0304-3959(03)00160-X PMID: 14499422
  42. Wasan, A.; Ossanna, M.; Raskin, J.; Wernicke, J.; Robinson, M.; Hall, J.; Edwards, S.; Lipsius, S.; Meyers, A.; McCarberg, B. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. Curr. Drug Saf., 2009, 4(1), 22-29. doi: 10.2174/157488609787354404 PMID: 19149522
  43. Cruccu, G.; Truini, A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther., 2017, 6(Suppl. 1), 35-42. doi: 10.1007/s40122-017-0087-0 PMID: 29178033
  44. Ferrell, B.A. Pain Management. In: Hazzard’s Geriatric Medicine and Gerontology; 7th ed; Halter, J.B.; Ouslander, J.G.; Studenski, S.; High, K.P.; Asthana, S.; Supiano, M.A., Eds.; McGraw-Hill Education: New York, 2017.
  45. Nicholson, B.; Verma, S. Comorbidities in chronic neuropathic pain. Pain Med., 2004, 5(Suppl. 1), S9-S27. doi: 10.1111/j.1526-4637.2004.04019.x PMID: 14996227
  46. Gallagher, R.; Apostle, N. Peripheral edema with pregabalin. CMAJ, 2013, 185(10), E506-E506. doi: 10.1503/cmaj.121232 PMID: 23128284
  47. Azmi, S.; ElHadd, K.T.; Nelson, A.; Chapman, A.; Bowling, F.L.; Perumbalath, A.; Lim, J.; Marshall, A.; Malik, R.A.; Alam, U. Pregabalin in the management of painful diabetic neuropathy: a narrative review. Diabetes Ther., 2019, 10(1), 35-56. doi: 10.1007/s13300-018-0550-x PMID: 30565054
  48. Usmani, H.; Amir, S.H.; Nasreen, F.; Siddiqi, S.; Hasan, M.; Tauheed, N. Pregabalin versus oxcarbazepine in painful diabetic neuropathy in elderly population: Efficacy and safety in terms of pain relief, cognitive function, and overall quality of life. Indian J. Pain, 2018, 32(1), 40. doi: 10.4103/ijpn.ijpn_76_17
  49. Nasreddine, W.; Beydoun, A. Oxcarbazepine in neuropathic pain. Expert Opin. Investig. Drugs, 2007, 16(10), 1615-1625. doi: 10.1517/13543784.16.10.1615 PMID: 17922625
  50. Gilron, I.; Bailey, J.M.; Tu, D.; Holden, R.R.; Jackson, A.C.; Houlden, R.L. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet, 2009, 374(9697), 1252-1261. doi: 10.1016/S0140-6736(09)61081-3 PMID: 19796802
  51. Rowbotham, M.C.; Goli, V.; Kunz, N.R.; Lei, D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain, 2004, 110(3), 697-706. doi: 10.1016/j.pain.2004.05.010 PMID: 15288411
  52. Aiyer, R.; Barkin, R.L.; Bhatia, A. Treatment of neuropathic pain with venlafaxine: A systematic review. Pain Med., 2017, 18(10), 1999-2012. doi: 10.1093/pm/pnw261 PMID: 27837032
  53. Cheng, C.W.H.; Wong, C.S.M.; Hui, G.K.M.; Chung, E.K.N.; Wong, S.H.S. Fibromyalgia: is it a neuropathic pain? Pain Manag. (Lond.), 2018, 8(5), 377-388. doi: 10.2217/pmt-2018-0024 PMID: 30212264
  54. Datta Gupta, A.; Edwards, S.; Smith, J.; Snow, J.; Visvanathan, R.; Tucker, G.; Wilson, D. A Systematic review and meta-analysis of efficacy of botulinum toxin a for neuropathic Pain. Toxins, 2022, 14(1), 36. doi: 10.3390/toxins14010036 PMID: 35051013
  55. Egeo, G.; Fofi, L.; Barbanti, P. Botulinum neurotoxin for the treatment of neuropathic pain. Front. Neurol., 2020, 11, 716. doi: 10.3389/fneur.2020.00716 PMID: 32849195
  56. Didangelos, T.; Karlafti, E.; Kotzakioulafi, E.; Margariti, E.; Giannoulaki, P.; Batanis, G.; Tesfaye, S.; Kantartzis, K. Vitamin B12 supplementation in diabetic neuropathy: A 1-year, randomized, double-blind, placebo-controlled trial. Nutrients, 2021, 13(2), 395. doi: 10.3390/nu13020395 PMID: 33513879
  57. Miller, J.W. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B12 deficiency: clinical implications. Adv. Nutr., 2018, 9(4), 511S-518S. doi: 10.1093/advances/nmy023 PMID: 30032223
  58. Alvarez, M.; Sierra, O.R.; Saavedra, G.; Moreno, S. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: A cross-sectional study. Endocr. Connect., 2019, 8(10), 1324-1329. doi: 10.1530/EC-19-0382 PMID: 31518991
  59. Putz, Z.; Tordai, D.; Hajdú, N.; Vági, O.E.; Kempler, M.; Békeffy, M.; Körei, A.E.; Istenes, I.; Horváth, V.; Stoian, A.P.; Rizzo, M.; Papanas, N.; Kempler, P. Vitamin D in the prevention and treatment of diabetic neuropathy. Clin. Ther., 2022, 44(5), 813-823. doi: 10.1016/j.clinthera.2022.03.012 PMID: 35428527
  60. Putz, Z.; Martos, T.; Németh, N.; Körei, A.E.; Vági, O.E.; Kempler, M.S.; Kempler, P. Is there an association between diabetic neuropathy and low vitamin D levels? Curr. Diab. Rep., 2014, 14(10), 537. doi: 10.1007/s11892-014-0537-6 PMID: 25142719
  61. Garcion, E.; Wion-Barbot, N.; Montero-Menei, C.N.; Berger, F.; Wion, D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab., 2002, 13(3), 100-105. doi: 10.1016/S1043-2760(01)00547-1 PMID: 11893522
  62. Zhang, Y.; Gong, S.; He, L.; Zhou, M.; Guo, J.; Hoke, A.; Zhu, C. Nerve growth factor for neuropathic pain. Cochrane Libr., 2017, 2017(11), CDD12800. doi: 10.1002/14651858.CD012800
  63. Khan, N.; Smith, M. Neurotrophins and neuropathic pain: role in pathobiology. Molecules, 2015, 20(6), 10657-10688. doi: 10.3390/molecules200610657 PMID: 26065639
  64. McArthur, J.C.; Yiannoutsos, C.; Simpson, D.M.; Adornato, B.T.; Singer, E.J.; Hollander, H.; Marra, C.; Rubin, M.; Cohen, B.A.; Tucker, T.; Navia, B.A.; Schifitto, G.; Katzenstein, D.; Rask, C.; Zaborski, L.; Smith, M.E.; Shriver, S.; Millar, L.; Clifford, D.B.; Karalnik, I.J. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology, 2000, 54(5), 1080-1088. doi: 10.1212/WNL.54.5.1080 PMID: 10720278
  65. Riaz, S.; Malcangio, M.; Miller, M.; Tomlinson, D.R. A vitamin D 3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia, 1999, 42(11), 1308-1313. doi: 10.1007/s001250051443 PMID: 10550414
  66. Llewellyn, D.J.; Lang, I.A.; Langa, K.M.; Muniz-Terrera, G.; Phillips, C.L.; Cherubini, A.; Ferrucci, L.; Melzer, D. Vitamin D and risk of cognitive decline in elderly persons. Arch. Intern. Med., 2010, 170(13), 1135-1141. doi: 10.1001/archinternmed.2010.173 PMID: 20625021
  67. Wion, D.; Macgrogan, D.; Neveu, I.; Jehan, F.; Houlgatte, R.; Brachet, P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res., 1991, 28(1), 110-114. doi: 10.1002/jnr.490280111 PMID: 1904101
  68. Cornet, A.; Baudet, C.; Neveu, I.; Baron-Van Evercooren, A.; Brachet, P.; Naveilhan, P. 1,25‐dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J. Neurosci. Res., 1998, 53(6), 742-746. doi: 10.1002/(SICI)1097-4547(19980915)53:63.0.CO;2-# PMID: 9753201
  69. Saporito, M.S.; Brown, E.R.; Hartpence, K.C.; Wilcox, H.M.; Vaught, J.L.; Carswell, S. Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. Brain Res., 1994, 633(1-2), 189-196. doi: 10.1016/0006-8993(94)91539-3 PMID: 8137156
  70. Naveilhan, P.; Neveu, I.; Wion, D.; Brachet, P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport, 1996, 7(13), 2171-2175. doi: 10.1097/00001756-199609020-00023 PMID: 8930983
  71. Neveu, I.; Naveilhan, P.; Baudet, C.; Brachet, P.; Metsis, M. 1,25-Dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport, 1994, 6(1), 124-126. doi: 10.1097/00001756-199412300-00032 PMID: 7703399
  72. Wang, J.Y.; Wu, J.N.; Cherng, T.L.; Hoffer, B.J.; Chen, H.H.; Borlongan, C.V.; Wang, Y. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res., 2001, 904(1), 67-75. doi: 10.1016/S0006-8993(01)02450-7 PMID: 11516412
  73. El Soury, M.; Fornasari, B.E.; Carta, G.; Zen, F.; Haastert-Talini, K.; Ronchi, G. The role of dietary nutrients in peripheral nerve regeneration. Int. J. Mol. Sci., 2021, 22(14), 7417. doi: 10.3390/ijms22147417 PMID: 34299037
  74. Gao, Z.; Feng, Y.; Ju, H. The different dynamic changes of nerve growth factor in the dorsal horn and dorsal root ganglion leads to hyperalgesia and allodynia in diabetic neuropathic pain. Pain Physician, 2017, 20(4), E551-E561. PMID: 28535564
  75. Lee, P.; Chen, R. Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch. Intern. Med., 2008, 168(7), 771-772. doi: 10.1001/archinte.168.7.771 PMID: 18413561
  76. Alam, U.; Najam, O.; Al-Himdani, S.; Benoliel, S.; Jinadev, P.; Berry, J.L.; Kew, M.; Asghar, O.; Petropoulos, I.N.; Malik, R.A. Marked vitamin D deficiency in patients with diabetes in the UK: ethnic and seasonal differences and an association with dyslipidaemia. Diabet. Med., 2012, 29(10), 1343-1345. doi: 10.1111/j.1464-5491.2012.03692.x PMID: 22507464
  77. Ghadiri-Anari, A.; Mozafari, Z.; Gholami, S.; Khodaei, S.A.; Aboutorabi-zarchi, M.; Sepehri, F.; Nadjarzade, A.; Rahmanian, M.; Namiranian, N. Dose vitamin D supplementations improve peripheral diabetic neuropathy? A before-after clinical trial. Diabetes Metab. Syndr., 2019, 13(1), 890-893. doi: 10.1016/j.dsx.2018.12.014 PMID: 30641826
  78. Xiaohua, G.; Dongdong, L.; Xiaoting, N.; Shuoping, C.; Feixia, S.; Huajun, Y.; Qi, Z.; Zimiao, C. Severe vitamin D deficiency is associated with increased expression of inflammatory cytokines in painful diabetic peripheral neuropathy. Front. Nutr., 2021, 8, 612068. doi: 10.3389/fnut.2021.612068 PMID: 33777989
  79. Kweder, H.; Eidi, H. Vitamin D deficiency in elderly: Risk factors and drugs impact on vitamin D status. Avicenna J. Med., 2018, 8(4), 139-146. doi: 10.4103/ajm.AJM_20_18 PMID: 30319955
  80. Yammine, K.; Wehbe, R.; Assi, C. A systematic review on the efficacy of vitamin D supplementation on diabetic peripheral neuropathy. Clin. Nutr., 2020, 39(10), 2970-2974. doi: 10.1016/j.clnu.2020.01.022 PMID: 32089370
  81. Marchesi, N.; Govoni, S.; Allegri, M. Non‐drug pain relievers active on non‐opioid pain mechanisms. Pain Pract., 2022, 22(2), 255-275. doi: 10.1111/papr.13073 PMID: 34498362
  82. Hakimizad, R.; Soltani, R.; Khorvash, F.; Marjani, M.; Dastan, F. The effect of acetyl-L-carnitine, alpha-lipoic acid, and coenzyme Q10 combination in preventing anti-tuberculosis drug-induced hepatotoxicity: a randomized, double-blind, placebo-controlled clinical trial. Iran. J. Pharm. Res., 2021, 20(3), 431-440. doi: 10.22037/ijpr.2021.114618.14953 PMID: 34903999
  83. Colucci, W.J.; Gandour, R.D. Carnitine acetyltransferase: A review of its biology, enzymology, and bioorganic chemistry. Bioorg. Chem., 1988, 16(3), 307-334. doi: 10.1016/0045-2068(88)90018-1
  84. Virmani, M.A.; Biselli, R.; Spadoni, A.; Rossi, S.; Corsico, N.; Calvani, M.; Fattorossi, A.; De Simone, C.; Arrigoni-Martelli, E. Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol. Res., 1995, 32(6), 383-389. doi: 10.1016/S1043-6618(05)80044-1 PMID: 8736490
  85. Sima, A.A.; Ristic, H.; Merry, A.; Kamijo, M.; Lattimer, S.A.; Stevens, M.J.; Greene, D.A. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J. Clin. Invest., 1996, 97(8), 1900-1907. doi: 10.1172/JCI118621 PMID: 8621774
  86. Hart, A.M.; Wiberg, M.; Youle, M.; Terenghi, G. Systemic acetyl-l-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res., 2002, 145(2), 182-189. doi: 10.1007/s00221-002-1100-2 PMID: 12110958
  87. Di Cesare Mannelli, L.; Ghelardini, C.; Calvani, M.; Nicolai, R.; Mosconi, L.; Vivoli, E.; Pacini, A.; Bartolini, A. Protective effect of acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy. Eur. J. Neurosci., 2007, 26(4), 820-827. doi: 10.1111/j.1460-9568.2007.05722.x PMID: 17714181
  88. De Grandis, D.; Minardi, C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D., 2002, 3(4), 223-231. doi: 10.2165/00126839-200203040-00001 PMID: 12455197
  89. Sima, A.A.F.; Calvani, M.; Mehra, M.; Amato, A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care, 2005, 28(1), 89-94. doi: 10.2337/diacare.28.1.89 PMID: 15616239
  90. Li, S.; Chen, X.; Li, Q.; Du, J.; Liu, Z.; Peng, Y.; Xu, M.; Li, Q.; Lei, M.; Wang, C.; Zheng, S.; Zhang, X.; Yu, H.; Shi, J.; Tao, S.; Feng, P.; Tian, H. Effects of acetyl‐L‐carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double‐blind, controlled trial. J. Diabetes Investig., 2016, 7(5), 777-785. doi: 10.1111/jdi.12493 PMID: 27180954
  91. Rolim, L.C.S.P.; da Silva, E.M.K.; Flumignan, R.L.G.; Abreu, M.M.; Dib, S.A. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Libr., 2019, 2019(6), CD011265. doi: 10.1002/14651858.CD011265.pub2 PMID: 31201734
  92. Catania, V.E.; Malaguarnera, G.; Bertino, G.; Chisari, L.M.; Castorina, M.; Bonfiglio, C.; Cauli, O.; Malaguarnera, M. Acetyl-L-carnitine can slow the progression from prefrailty to frailty in older subjects. A randomized interventional clinical trial. Curr. Pharm. Des., 2022, 28(38), 3158-3166. doi: 10.2174/1381612828666220830092815 PMID: 36043711
  93. Ziegler, D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat. Endocrinol., 2004, 3(3), 173-189. doi: 10.2165/00024677-200403030-00005 PMID: 16026113
  94. Mijnhout, G.S.; Kollen, B.J.; Alkhalaf, A.; Kleefstra, N.; Bilo, H.J.G. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int. J. Endocrinol., 2012, 2012, 1-8. doi: 10.1155/2012/456279 PMID: 22331979
  95. Han, T.; Bai, J.; Liu, W.; Hu, Y. Therapy of endocrine disease: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur. J. Endocrinol., 2012, 167(4), 465-471. doi: 10.1530/EJE-12-0555 PMID: 22837391
  96. Elbadawy, A.M.; Abd Elmoniem, R.O.; Elsayed, A.M. Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters. Alex. J. Med., 2021, 57(1), 113-120. doi: 10.1080/20905068.2021.1907961
  97. Agathos, E.; Tentolouris, A.; Eleftheriadou, I.; Katsaouni, P.; Nemtzas, I.; Petrou, A.; Papanikolaou, C.; Tentolouris, N. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J. Int. Med. Res., 2018, 46(5), 1779-1790. doi: 10.1177/0300060518756540 PMID: 29517942
  98. Fattori, V.; Hohmann, M.; Rossaneis, A.; Pinho-Ribeiro, F.; Verri, W. Capsaicin: current understanding of its mechanisms and therapy of pain and other pre-clinical and clinical uses. Molecules, 2016, 21(7), 844. doi: 10.3390/molecules21070844 PMID: 27367653
  99. Chung, M.K.; Campbell, J. Use of capsaicin to treat pain: mechanistic and therapeutic considerations. Pharmaceuticals (Basel), 2016, 9(4), 66. doi: 10.3390/ph9040066 PMID: 27809268
  100. Baranidharan, G.; Das, S.; Bhaskar, A. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther. Adv. Neurol. Disord., 2013, 6(5), 287-297. doi: 10.1177/1756285613496862 PMID: 23997814
  101. Epstein, J.B.; Marcoe, J.H. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg. Oral Med. Oral Pathol., 1994, 77(2), 135-140. doi: 10.1016/0030-4220(94)90275-5 PMID: 8139830
  102. Campbell, C.M.; Kipnes, M.S.; Stouch, B.C.; Brady, K.L.; Kelly, M.; Schmidt, W.K.; Petersen, K.L.; Rowbotham, M.C.; Campbell, J.N. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain, 2012, 153(9), 1815-1823. doi: 10.1016/j.pain.2012.04.014 PMID: 22683276
  103. Mankowski, C.; Poole, C.D.; Ernault, E.; Thomas, R.; Berni, E.; Currie, C.J.; Treadwell, C.; Calvo, J.I.; Plastira, C.; Zafeiropoulou, E.; Odeyemi, I. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol., 2017, 17(1), 80. doi: 10.1186/s12883-017-0836-z PMID: 28431564
  104. Vinik, A.I.; Perrot, S.; Vinik, E.J.; Pazdera, L.; Jacobs, H.; Stoker, M.; Long, S.K.; Snijder, R.J.; van der Stoep, M.; Ortega, E.; Katz, N. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol., 2016, 16(1), 251. doi: 10.1186/s12883-016-0752-7 PMID: 27919222
  105. Musharraf, M.U.; Ahmad, Z.; Yaqub, Z. Comparison of topical capsaicin and topical turpentine Oil for treatment of painful diabetic neuropathy. J. Ayub Med. Coll. Abbottabad, 2017, 29(3), 384-387. PMID: 29076666
  106. Gálvez, R.; Navez, M.L.; Moyle, G.; Maihöfner, C.; Stoker, M.; Ernault, E.; Nurmikko, T.J.; Attal, N. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain. Clin. J. Pain, 2017, 33(10), 921-931. doi: 10.1097/AJP.0000000000000473 PMID: 28872473
  107. Derry, S.; Lloyd, R.; Moore, R.A.; McQuay, H.J. Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2009, CD007393(4), CD007393. doi: 10.1002/14651858.CD007393.pub2 PMID: 19821411
  108. Dludla, P.V.; Nkambule, B.B.; Cirilli, I.; Marcheggiani, F.; Mabhida, S.E.; Ziqubu, K.; Ntamo, Y.; Jack, B.; Nyambuya, T.M.; Hanser, S.; Mazibuko-Mbeje, S.E. Capsaicin, its clinical significance in patients with painful diabetic neuropathy. Biomed. Pharmacother., 2022, 153, 113439. doi: 10.1016/j.biopha.2022.113439 PMID: 36076554
  109. Yuan, L.J.; Qin, Y.; Wang, L.; Zeng, Y.; Chang, H.; Wang, J.; Wang, B.; Wan, J.; Chen, S.H.; Zhang, Q.Y.; Zhu, J.D.; Zhou, Y.; Mi, M.T. Capsaicin-containing chili improved postprandial hyperglycemia, hyperinsulinemia, and fasting lipid disorders in women with gestational diabetes mellitus and lowered the incidence of large-for-gestational-age newborns. Clin. Nutr., 2016, 35(2), 388-393. doi: 10.1016/j.clnu.2015.02.011 PMID: 25771490
  110. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 1997, 389(6653), 816-824. doi: 10.1038/39807 PMID: 9349813
  111. Caterina, M.J.; Leffler, A.; Malmberg, A.B.; Martin, W.J.; Trafton, J.; Petersen-Zeitz, K.R.; Koltzenburg, M.; Basbaum, A.I.; Julius, D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science, 2000, 288(5464), 306-313. doi: 10.1126/science.288.5464.306 PMID: 10764638
  112. Wang, S.; Joseph, J.; Diatchenko, L.; Ro, J.Y.; Chung, M.K. Agonist-dependence of functional properties for common nonsynonymous variants of human transient receptor potential vanilloid 1. Pain, 2016, 157(7), 1515-1524. doi: 10.1097/j.pain.0000000000000556 PMID: 26967694
  113. Peppin, J.F.; Pappagallo, M. Capsaicinoids in the treatment of neuropathic pain: a review. Ther. Adv. Neurol. Disord., 2014, 7(1), 22-32. doi: 10.1177/1756285613501576 PMID: 24409200
  114. Yong, Y.L.; Tan, L.T.H.; Ming, L.C.; Chan, K.G.; Lee, L.H.; Goh, B.H.; Khan, T.M. The effectiveness and safety of topical capsaicin in postherpetic neuralgia: a systematic review and meta-analysis. Front. Pharmacol., 2017, 7, 538. doi: 10.3389/fphar.2016.00538 PMID: 28119613
  115. Skaper, S.D.; Facci, L.; Fusco, M.; della Valle, M.F.; Zusso, M.; Costa, B.; Giusti, P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology, 2014, 22(2), 79-94. doi: 10.1007/s10787-013-0191-7 PMID: 24178954
  116. Hansen, H.S. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp. Neurol., 2010, 224(1), 48-55. doi: 10.1016/j.expneurol.2010.03.022 PMID: 20353771
  117. Borrelli, F.; Romano, B.; Petrosino, S.; Pagano, E.; Capasso, R.; Coppola, D.; Battista, G.; Orlando, P.; Di Marzo, V.; Izzo, A.A. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br. J. Pharmacol., 2015, 172(1), 142-158. doi: 10.1111/bph.12907 PMID: 25205418
  118. Romero, T.R.L.; Duarte, I.D.G. N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation. J. Pharmacol. Sci., 2012, 118(2), 156-160. doi: 10.1254/jphs.11150FP PMID: 22343363
  119. Romero, T.R.L.; Galdino, G.S.; Silva, G.C.; Resende, L.C.; Perez, A.C.; Cortes, S.F.; Duarte, I.D.G. Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. J. Neurosci. Res., 2012, 90(7), 1474-1479. doi: 10.1002/jnr.22797 PMID: 22411529
  120. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain, 2008, 139(3), 541-550. doi: 10.1016/j.pain.2008.06.003 PMID: 18602217
  121. Gatti, A.; Lazzari, M.; Gianfelice, V.; Di Paolo, A.; Sabato, E.; Sabato, A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med., 2012, 13(9), 1121-1130. doi: 10.1111/j.1526-4637.2012.01432.x PMID: 22845893
  122. Marini, I.; Bartolucci, M.L.; Bortolotti, F.; Gatto, M.R.; Bonetti, G.A. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J. Orofac. Pain, 2012, 26(2), 99-104. PMID: 22558609
  123. Schifilliti, C.; Cucinotta, L.; Fedele, V.; Ingegnosi, C.; Luca, S.; Leotta, C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res. Treat., 2014, 2014, 1-5. doi: 10.1155/2014/849623 PMID: 24804094
  124. D’Amico, R.; Impellizzeri, D.; Cuzzocrea, S.; Di Paola, R. Aliamides update: Palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int. J. Mol. Sci., 2020, 21(15), 5330. doi: 10.3390/ijms21155330 PMID: 32727084

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers